Review Article

American Journal of Cardiovascular Drugs

, Volume 3, Issue 3, pp 193-200

First online:

Preventing Renal Dysfunction in Patients with Hypertension

Clinical Implications from the Early AASK Trial Results
  • Janice P. LeaAffiliated withEmory University School of Medicine Email author 
  • , Denyse T. BrownAffiliated withUniversity of Alabama at Birmingham
  • , Michael LipkowitzAffiliated withMount Sinai School of Medicine
  • , John MiddletonAffiliated withUniversity of Texas-Southwestern
  • , Keith NorrisAffiliated withMartin Luther King, Jr/Charles Drew University
  • , AASK Study Group

Rent the article at a discount

Rent now

* Final gross prices may vary according to local VAT.

Get Access


Strategies to delay progression of established renal disease have primarily been directed at examining the class of antihypertensive therapy and/or the level of blood pressure control. In diabetic renal disease many trials have noted a protective role of ACE inhibitor-based therapy over non-ACE inhibitor-based therapy. This paper reviews recent clinical trials evaluating hypertension-related kidney disease including the interim results of the African-American Study of Kidney Diseases and Hypertension (AASK) Study, to date the largest prospective study of African-American patients with kidney disease due to hypertension. This trial reports a renoprotective effect of ACE inhibitor-based therapy over calcium-channel antagonist- based therapy. The renoprotective effect of ACE inhibitor-based therapy may, in part, be due to their antiproteinuric effect independent of blood pressure lowering.